Bloomberg Estimate of SalesThese Bloomberg numbers have historically been less than helpful but I do take a look every now and again to see what they are suggesting. For Q1, that will be reported in the middle of next month, US Trogarzo sales are likely to be about flat but Egrifta sales had a nice jump higher probably about 10% higher. Foreign Trogarzo sales may also help year over year comparisons. TH's comments about Q1 sales sounded more optimistic than those numbers suggest, however, so hopefully, we will see better results and TH will push their annual guidance number a bit higher too.
Early March sales of both Trogarzo and Egrifta looked better as well so the second quarter seems to be off to a good start. Again, these numbers are not fully trustworthy and may not line up with what the company actually reports.
Also, it is better for Egrifta sales to be good versus the much less profitable Trogarzo sales (proceeds from these sales need to be shared with Taimed). So, I am happy to see that Egrifta seems to be selling a bit better.